Shots:
- Candel Therapeutics has entered into a $100M royalty funding agreement with RTW Investments, contingent on FDA approval of Aglatimagene Besadenovec (CAN-2409) for intermediate- to high-risk localized prostate cancer
- As per the deal, RTW will receive a capped, tiered single-digit percentage of US annual net sales of aglatimagene. Candel Plans to submit a BLA for Aglatimagene Besadenovec  in Q4,26Â
- Aglatimagene besadenovec has completed successful P-IIa trials in NSCLC and PDAC, and a pivotal PBO-controlled P-III trial in localized prostate cancer under a Special Protocol Assessment with the FDA
Ref: Candel Therapeutics | Image: Candel Therapeutics and RTW | Press Release
Related News: Covetrus to Merge with Cencora’s MWI Animal Health in a $3.5B Deal
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
